Spinal Cord Tumors

Spinal cord tumors are neoplastic masses arising within or adjacent to the spinal cord, its coverings, or the vertebral column, resulting in progressive myelopathy and pain. They are classified by their anatomical location as extradural, intradural-extramedullary, or intramedullary. Extradural tumors (e.g., vertebral osteosarcoma, fibrosarcoma, plasma cell tumors) arise from vertebral bone or epidural tissues, compressing the cord externally. Intradural-extramedullary tumors (e.g., meningioma, nerve sheath tumors) grow within the dura but outside the cord parenchyma, often causing characteristic displacement. Intramedullary tumors (e.g., astrocytoma, ependymoma) originate within the spinal cord tissue itself, causing diffuse expansion. Surgical management aims for cytoreduction or excision, decompression, and histopathologic diagnosis, with adjunctive therapies (radiation, chemotherapy) as indicated. The clinical presentation typically includes progressive ataxia, proprioceptive deficits, spinal hyperesthesia, and eventual paresis or paralysis, with the clinical course influenced by tumor growth rate and location.

The etiology of spinal cord tumors is largely unknown, but several factors are implicated. Genetic mutations and hereditary predispositions are recognized in certain breeds (e.g., meningiomas in dogs, lymphomas in cats). Viral oncogenesis has been suggested for feline lymphoma (FeLV) and possibly for other tumors. Environmental factors, such as exposure to carcinogens or radiation, may contribute, though rarely documented. Chronic inflammation or trauma has been hypothesized to trigger neoplastic transformation in some cases, but evidence is limited. For vertebral tumors, primary bone neoplasia (osteosarcoma, chondrosarcoma) often arises spontaneously, with no clear predisposing cause. Metastatic spread from distant primary tumors (e.g., mammary, prostatic, pulmonary) can also seed the vertebral column or epidural space. In cats, vaccine-associated sarcomas can invade the vertebral canal if located near the spine. Overall, the etiology is multifactorial, involving genetic, epigenetic, and possibly environmental interactions.

Spinal cord tumors are relatively uncommon in small animals, accounting for approximately 2-5% of all canine tumors and a smaller percentage in cats. They occur more frequently in middle-aged to older animals, with a median age of 6-9 years in dogs and 8-10 years in cats. There is no strong sex predilection, though some studies suggest a slight male predominance for certain tumor types. Breed predispositions include large-breed dogs (e.g., Golden Retrievers, Boxers, German Shepherds) for vertebral osteosarcoma, and brachycephalic breeds (e.g., Boxers, Boston Terriers) for meningiomas. In cats, meningiomas are more common in Domestic Shorthairs, and lymphoma is seen in FeLV-positive cats. Intramedullary tumors are rare but can occur in young to middle-aged dogs. The incidence of spinal lymphoma is higher in cats than dogs, often as part of multicentric disease. Overall, the epidemiology reflects the underlying tumor biology, with age, breed, and viral status playing significant roles.

The pathophysiology of spinal cord tumors involves progressive compression, ischemia, and infiltration of neural tissue. Extradural tumors expand within the vertebral canal, directly compressing the spinal cord and its vasculature. This leads to venous congestion, edema, and demyelination, followed by axonal degeneration and necrosis as compression worsens. Intradural-extramedullary tumors, such as meningiomas, grow slowly and cause compression by occupying space within the dura, often leading to displacement of the cord and interference with cerebrospinal fluid flow. Intramedullary tumors infiltrate the cord parenchyma, disrupting neural pathways and causing cellular dysfunction. Tumor growth also induces a local inflammatory response, with release of cytokines and growth factors that exacerbate tissue damage. As the tumor enlarges, it may cause vertebral bone lysis or pathological fracture, further compromising stability. The clinical signs correlate with the rate of growth and the spinal cord segment involved; cervical lesions may cause tetraplegia, while thoracolumbar lesions cause paraplegia. Pain arises from meningeal irritation, nerve root compression, or vertebral periosteal stretching. Without intervention, progressive neurological deterioration leads to irreversible spinal cord damage.

Predisposing factors for spinal cord tumors include age, breed, genetic susceptibility, and viral infections. Older animals are at higher risk due to accumulated genetic mutations and decreased immune surveillance. Certain breeds have a genetic predisposition to specific tumor types, such as meningiomas in Boxers and osteosarcomas in large-breed dogs. FeLV infection in cats significantly increases the risk of spinal lymphoma. Prior radiation exposure is a rare but recognized risk factor for secondary tumor development. Chronic inflammation or trauma may create a microenvironment conducive to neoplasia, though this is not well-established. Obesity and hormonal factors have been suggested but lack strong evidence. Additionally, animals with a history of other primary tumors may develop metastatic spinal lesions. Overall, the presence of these factors should raise clinical suspicion, but their absence does not rule out spinal neoplasia.

Clinical signs of spinal cord tumors are progressive and depend on the tumor location and rate of growth. Common signs include spinal hyperesthesia (pain on palpation or movement), ataxia, proprioceptive deficits (knuckling, crossing over), paresis or paralysis, and urinary/fecal incontinence. Cervical tumors may cause neck pain, reluctance to move, and tetraplegia. Thoracolumbar tumors typically present with pelvic limb ataxia and paresis, progressing to paraplegia. Lumbosacral tumors can cause nerve root signs, such as sciatic neurology, and cauda equina syndrome. Intramedullary tumors often present with early, severe neurological deficits out of proportion to pain. Neurological examination reveals upper motor neuron signs (spasticity, hyperreflexia) for lesions cranial to the L4 spinal cord segment, and lower motor neuron signs (flaccidity, hyporeflexia) for lesions caudal to L4. Pain is a prominent feature, especially with extradural tumors involving the vertebral bone or nerve roots. As the tumor progresses, respiratory compromise may occur with high cervical lesions. Systemic signs such as weight loss, lethargy, and fever may be present with metastatic or paraneoplastic syndromes.

Differential diagnoses for spinal cord tumors include intervertebral disc disease (IVDD), which typically has an acute onset and is more common in chondrodystrophic breeds; imaging shows disc degeneration and extrusion. Meningomyelitis (infectious or immune-mediated) can mimic tumors, with CSF analysis showing inflammation and negative imaging for a mass. Spinal abscess or epidural empyema presents with fever, leukocytosis, and a contrast-enhancing lesion on MRI. Vertebral fractures or luxations are usually traumatic and show malalignment on radiographs. Fibrocartilaginous embolic myelopathy (FCEM) causes acute, non-painful myelopathy with a suspected ischemic event. Syringomyelia or hydromyelia may cause similar signs but is often associated with Chiari-like malformation. Spinal cord infarction (ischemic myelopathy) presents acutely with non-progressive deficits. Additionally, primary bone diseases such as discospondylitis (infection of the disc and adjacent vertebrae) cause pain and neurological signs, with characteristic radiographic changes. Each differential is ruled out by a combination of history, neurological examination, advanced imaging, and CSF analysis.

The diagnostic algorithm for spinal cord tumors begins with a thorough history and complete neurological examination to localize the lesion. If spinal disease is suspected, survey radiographs of the spine are obtained to assess for vertebral lysis, pathological fractures, or soft tissue masses. However, radiographs are often normal in early cases. The next step is advanced imaging, with MRI being the gold standard for spinal cord tumors. MRI provides detailed soft tissue contrast, allowing identification of the tumor's location (extradural, intradural-extramedullary, intramedullary), extent, and relationship to the spinal cord. CT is useful for evaluating bony involvement and for surgical planning, especially with 3D reconstructions. If a tumor is suspected, CSF analysis is performed, but it is often non-specific; however, it can help rule out inflammation. In some cases, a tissue biopsy is needed for definitive diagnosis, either via CT-guided needle biopsy or surgical biopsy. For suspected lymphoma, PCR for antigen receptor rearrangements (PARR) on CSF or tissue can be diagnostic. The algorithm emphasizes early advanced imaging to expedite diagnosis and surgical planning.

Laboratory findings in spinal cord tumors are often non-specific but can support the diagnosis and assess surgical risk. Complete blood count may reveal anemia of chronic disease, leukocytosis, or lymphopenia. Serum biochemistry may show hypercalcemia (with certain tumors like lymphoma or multiple myeloma), elevated alkaline phosphatase (with bone tumors), or hypoalbuminemia. Urinalysis may detect proteinuria or hematuria if there is urinary tract infection secondary to neurological dysfunction. Coagulation profile (PT/aPTT) is recommended to rule out coagulopathies, especially if surgery is planned. CSF analysis is crucial: it may show increased protein concentration, pleocytosis (lymphocytic or neutrophilic), and occasionally neoplastic cells, though cytology is often inconclusive. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated but are not specific. For suspected infectious causes, serology or PCR for FeLV/FIV in cats is indicated. Overall, laboratory findings help exclude other causes and prepare the patient for anesthesia and surgery.

Imaging is essential for diagnosing spinal cord tumors. Survey radiographs may show vertebral lysis, pathological fractures, or an enlarged vertebral canal, but they are insensitive. Myelography, historically used, has been largely replaced by advanced imaging. CT provides excellent bone detail and is useful for detecting vertebral tumors and assessing spinal stability; contrast-enhanced CT can identify epidural masses. MRI is the modality of choice, offering superior soft tissue contrast. On MRI, extradural tumors appear as masses compressing the cord, often with contrast enhancement. Intradural-extramedullary tumors, such as meningiomas, are well-defined, contrast-enhancing masses that displace the cord. Intramedullary tumors cause cord expansion with variable enhancement. MRI also helps differentiate tumors from other lesions like disc herniation or inflammation. For surgical planning, CT with 3D reconstruction is invaluable for assessing vertebral anatomy and planning screw placement. In some cases, fluoroscopy or intraoperative ultrasound can aid in tumor localization. Advanced imaging is critical for determining resectability and guiding surgical approach.

Cytology and histopathology are essential for definitive diagnosis of spinal cord tumors. Fine-needle aspiration of an extradural mass, if accessible, can provide a cytological diagnosis, especially for lymphoma or plasma cell tumors. However, for intradural or intramedullary tumors, surgical biopsy is required. Histopathological examination of the tumor tissue reveals the cell type, grade, and mitotic index. Meningiomas are typically benign, well-circumscribed, and show whorls of meningothelial cells. Nerve sheath tumors (schwannomas, neurofibromas) show spindle cells with Antoni A and B patterns. Astrocytomas and ependymomas are glial tumors with variable malignancy. Osteosarcomas show osteoid production by malignant osteoblasts. Lymphomas are characterized by sheets of neoplastic lymphocytes, often with immunophenotyping (B-cell or T-cell). Histopathology also assesses surgical margins, which is crucial for prognosis. Immunohistochemistry (e.g., GFAP for astrocytomas, CD3/CD79a for lymphomas) can refine the diagnosis. In cases of suspected metastatic disease, biopsy of the primary tumor may be indicated.

Treatment of spinal cord tumors is multimodal, with surgery playing a central role. The primary goal is decompression of the spinal cord and, when possible, complete excision of the tumor. For extradural tumors, a dorsal laminectomy or hemilaminectomy is performed to access the vertebral canal. The tumor is removed piecemeal or en bloc if feasible, with care to preserve neural tissue. For intradural-extramedullary tumors, a durotomy is performed after laminectomy, and the tumor is microsurgically dissected from the cord. Intramedullary tumors are challenging; a myelotomy may be attempted for well-circumscribed tumors, but complete excision is often impossible. In cases of vertebral tumors, partial or total vertebrectomy with stabilization may be required, using plates, screws, or pins and polymethylmethacrylate. Surgical approaches are based on the tumor location: cervical, thoracolumbar, or lumbosacral. Postoperative pain management includes opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h), NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h), and local anesthetics (e.g., epidural morphine 0.1 mg/kg). Adjunctive therapies include radiation therapy for incompletely excised tumors or radiosensitive types (e.g., lymphoma), and chemotherapy for systemic disease (e.g., lymphoma, osteosarcoma). Physical rehabilitation is crucial for recovery, including passive range of motion, massage, and assisted walking. The surgical plan must be tailored to the individual patient, considering tumor type, location, and neurological status.

The prognosis for spinal cord tumors varies widely depending on tumor type, location, and treatment. Meningiomas, if completely excised, have a good prognosis with median survival times of 20-30 months. Nerve sheath tumors have a guarded prognosis, with recurrence common if excision is incomplete. Intramedullary tumors generally have a poor prognosis due to difficulty in complete resection; median survival is often less than 6 months. Extradural tumors like osteosarcoma have a poor prognosis, with median survival of 4-6 months even with aggressive surgery and adjunctive therapy. Lymphoma is chemosensitive, and with combination chemotherapy, median survival can be 6-12 months. Negative prognostic indicators include high tumor grade, incomplete resection, intramedullary location, and severe neurological deficits at presentation. Postoperative complications such as infection, hemorrhage, or spinal instability can worsen outcomes. Early diagnosis and surgical intervention improve the chances of a favorable outcome. Overall, the prognosis is guarded to poor for most spinal cord tumors, but some patients achieve good quality of life for extended periods.

Postoperative follow-up for spinal cord tumor patients is critical. Immediately after surgery, patients are monitored in the ICU for neurological status, pain, and complications. Sutures are removed 10-14 days postoperatively. Neurological examinations are performed at 2, 4, 8, and 12 weeks, then every 3-6 months. Serial imaging (MRI or CT) is recommended at 3-6 months to assess for recurrence, especially if the tumor was incompletely excised. Activity restriction is enforced for 4-6 weeks, with gradual increase in exercise. Physical rehabilitation, including passive range of motion, massage, and therapeutic exercises, is initiated early and continued for several months. For patients receiving radiation or chemotherapy, regular monitoring of blood counts and organ function is necessary. Long-term follow-up includes monitoring for urinary tract infections, decubital ulcers, and muscle atrophy. Owners are educated on signs of recurrence, such as worsening neurological function or pain. The follow-up schedule is tailored to the individual patient's tumor type and treatment plan.

Clinical pearls: 1) Always perform a thorough neurological examination to localize the lesion before imaging. 2) MRI is essential for surgical planning; CT alone may miss intradural tumors. 3) For extradural tumors, a hemilaminectomy provides adequate exposure with less instability than dorsal laminectomy. 4) Use microsurgical techniques and bipolar cautery to minimize spinal cord trauma. 5) For intradural tumors, a durotomy should be performed carefully to avoid damaging the cord. 6) Consider intraoperative ultrasound to localize intramedullary tumors. 7) For vertebral tumors, stabilize the spine after tumor removal to prevent pathological fracture. 8) Administer perioperative antibiotics (e.g., cefazolin 22 mg/kg IV q90min) to prevent infection. 9) Use multimodal analgesia to manage pain effectively. 10) Early referral to a veterinary neurologist or surgeon improves outcomes. Pitfalls: 1) Delaying advanced imaging can lead to irreversible spinal cord damage. 2) Incomplete excision of meningiomas leads to recurrence; strive for complete removal. 3) Aggressive resection of intramedullary tumors can cause severe neurological deficits; weigh benefits vs. risks. 4) Failure to stabilize the spine after vertebral tumor removal can result in instability and worsening signs. 5) Overlooking concurrent diseases (e.g., urinary tract infection) can complicate recovery. 6) Inadequate pain management can lead to self-trauma and delayed healing. 7) Not monitoring for postoperative hemorrhage or edema can lead to acute deterioration. 8) Discontinuing antibiotics prematurely can cause surgical site infection. 9) Ignoring the need for physical rehabilitation can prolong recovery. 10) Failing to communicate realistic prognosis to owners can lead to dissatisfaction.

Perioperative drug protocols for spinal cord tumor surgery are based on Plumb's Veterinary Drug Handbook. Prophylactic antibiotics: cefazolin 22 mg/kg IV at induction and every 90 minutes during surgery. Postoperative antibiotics: if infection is a concern, continue cephalexin 22 mg/kg PO q8h for 7-10 days. Analgesics: opioids such as hydromorphone 0.05-0.1 mg/kg IV q4-6h, or fentanyl CRI at 2-5 mcg/kg/hr. NSAIDs: carprofen 2.2 mg/kg PO q12h, or meloxicam 0.1 mg/kg PO q24h, starting 24 hours after surgery if no contraindications. Local anesthetics: epidural morphine 0.1 mg/kg or bupivacaine 1 mg/kg (diluted) for intraoperative and postoperative analgesia. Muscle relaxants: methocarbamol 15-20 mg/kg PO q8h for muscle spasms. Corticosteroids: dexamethasone 0.1-0.2 mg/kg IV q24h for spinal cord edema, but use cautiously due to side effects. Gastroprotectants: omeprazole 1 mg/kg PO q12h or famotidine 0.5 mg/kg PO q12h. Antiemetics: maropitant 1 mg/kg PO q24h if needed. For chemotherapy protocols (e.g., lymphoma): CHOP-based protocols with L-asparaginase 400 IU/kg SC, vincristine 0.5-0.7 mg/m² IV, cyclophosphamide 200-250 mg/m² IV, doxorubicin 30 mg/m² IV, and prednisone 2 mg/kg PO q24h tapering. For osteosarcoma: carboplatin 300 mg/m² IV every 3 weeks. Adjust dosages for renal or hepatic impairment. Monitor for myelosuppression and gastrointestinal toxicity.

Landmark studies on spinal cord tumors in dogs and cats include: 1) A retrospective study by Levy et al. (1997) on 82 dogs with spinal cord tumors, reporting that meningiomas had a median survival of 21 months after surgical excision, while intramedullary tumors had a poor prognosis. 2) A study by Pancotto et al. (2013) on MRI features of spinal cord tumors, demonstrating that MRI accurately predicts tumor location and aids in surgical planning. 3) A study by Rossmeisl et al. (2007) on surgical treatment of intradural-extramedullary tumors, showing that complete excision of meningiomas results in long-term control. 4) A study by Kippenes et al. (2003) on vertebral osteosarcoma, reporting median survival of 5 months with surgery and chemotherapy. 5) A study by Marioni-Henry et al. (2008) on spinal lymphoma in cats, showing that chemotherapy with CHOP protocol results in remission rates of 70-80%. 6) ACVS consensus guidelines recommend MRI as the gold standard for diagnosis and surgical planning. 7) A meta-analysis by da Costa et al. (2014) on surgical outcomes for spinal cord tumors, emphasizing the importance of early intervention and complete resection. 8) A study by Bagley et al. (2009) on radiation therapy for incompletely excised tumors, showing improved survival with adjunctive radiation. These studies underscore the need for a multimodal approach and the prognostic significance of tumor type and surgical margins.